Catalysts / SVRA
Upcoming FDA decisions and readouts we track for Savara Inc., each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Savara Inc. (SVRA, listed on Nasdaq). It concerns Molgramostim (Autoimmune pulmonary alveolar proteinosis (aPAP)).
First on the list: the PDUFA date for Molgramostim (Autoimmune pulmonary alveolar proteinosis (aPAP)), listed for 22 Nov 2026 by a secondary source, not yet confirmed against the company's own filing.
The row links to a third-party catalyst calendar. It still needs confirming against the company's own filing. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Savara Inc. SVRA · Nasdaq | Molgramostim | Autoimmune pulmonary alveolar proteinosis (aPAP) | 22 Nov 2026 in 46d |
PDUFA date | Reported | Catalyst calendar ↗ | Yes |
FreeBioList